Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — Shareholder Meeting (February 2013)
26 slides from Simulations Plus's shareholder meeting presentation, Feb 19, 2013
Slide 1: Annual Shareholders' Meeting February 15, 2013
Simulations Plus, Inc. (NASDAQ:SLP) Annual Shareholders’ Meeting February 15, 2013
Slide 2: Agenda
• Welcome and Introductions • Discussion of Voting Issues • Chairman’s Remarks • Questions & Answers • Adjournment of Official Meeting Agenda
Slide 3: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to su
Slide 4: Management & Directors
Management & Directors • Board of Directors: – David Z. D’Argenio, Ph.D., Director • Professor, Biomedical Engineering, USC • Director, Co - Director, Biological Simulation Resource Center, USC since 1985 – H. Wayne Rosenberger, Director • Sr. Regional VP of American Security Bank (ret.) – David Ral
Slide 5: Outside Counsels
• Registered Independent Auditors • Rose, Snyder & Jacobs, Encino, CA • Tax Specialists • Rabbani, Inc., Los Angeles, CA • Legal Counsel • Procopio , Cory, Hargreaves & Savitch LLP Outside Counsels
Slide 6: Discussion of Voting Issues
Candidates for Board of Directors remain unchanged: • David Z. D’Argenio, Ph.D. • David Ralph, Ph.D. • H. Wayne Rosenberger • Virginia E. Woltosz, MBA • Walter S. Woltosz, MS, MAS • Outside auditor: • Rose, Snyder, Jacobs • There are no other voting issues • Votes already received by proxy have resu
Slide 7: FY12 compared to FY11
• FY12 compared to FY11: – Sales up 8.1% to Record Fiscal Year at $9.45 MM from $8.74 MM – Gross profit up 11.1% to $7.94 million from $7.18 million – SG&A up 6.1% to $3.38 million from $3.19 million • Legal fees for attempted acquisition of Entelos’ assets in bankruptcy court • Final payment to M&A
Slide 8: Income Statement FY2012 vs FY2011
Income Statement FY2012 vs FY2011 ($ millions) FY12 FY11 Net sales 9.449 8.739 Gross profit 7.939 7.180 Gross profit margin 84.0% 82.2% SG&A 3.379 3.186* R&D 0.948 0.464* Total operating expenses 4.327 3.650 Income from continuing operations 3.612 3.530 Other income 0.343 0.168 Results of discontinu
Slide 9: Revenues by Fiscal Year
$3.2 $5.7 $6.1 $6.3 $7.6 $8.7 $9.5 2006 2007 2008 2009 2010 2011 2012 $ Millions Revenues by Fiscal Year (pro forma prior to 2012)
Slide 10: Revenues by Quarter
Revenues by Quarter (pro forma prior to 2012) $1.4 $1.6 $2.0 $1.1 $1.4 $1.8 $2.0 $1.1 $1.7 $2.2 $2.3 $1.3 $2.1 $2.6 $2.6 $1.4 $0 $1 $2 $3 Q1 Q2 Q3 Q4 2008 2009 2010 2011 2012 $2.77 $2.77 $2.77 $2.77 $1.64 $2.2 $2.79
Slide 11: Gross Profit by Fiscal Year
$5.2 $6.4 $7.2 $7.9 2009 2010 2011 2012 $ M i l l i o n s 2009 2010 2011 2012 Gross Profit by Fiscal Year (pro forma prior to 2012)
Slide 12: Gross Profit by Fiscal Quarter
Gross Profit by Fiscal Quarter (pro forma prior to 2012) $1.24 $1.53 $1.75 $0.71 $1.45 $1.93 $1.97 $1.07 $1.70 $2.21 $2.21 $1.12 $1.90 $2.39 $2.33 $1.32 Q1 Q2 Q3 Q4 2009 2010 2011 2012
Slide 13: EBITDA by Fiscal Year
$2.4 $3.6 $4.4 $4.9 2009 2010 2011 2012 $ M i l l i o n s 2009 2010 2011 2012 EBITDA by Fiscal Year (pro forma prior to 2012)
Slide 14: EBITDA by Fiscal Quarter
EBITDA by Fiscal Quarter $0.55 $0.73 $0.93 $0.20 $0.73 $1.28 $1.23 $0.36 $1.00 $1.48 $1.48 $0.33 $1.11 $1.33 $1.40 $0.55 Q1 Q2 Q3 Q4 2009 2010 2011 2012
Slide 15: Net Income by Fiscal Year
$0.4 $1.3 $1.7 $2.0 $2.2 $2.6 $3.0 $0.0 $0.5 $1.0 $1.5 $2.0 $2.5 $3.0 $3.5 2006 2007 2008 2009 2010 2011 2012 $ Millions Net Income by Fiscal Year (pro forma prior to 2012)
Slide 16: Net Income by Fiscal Quarter
Net Income by Fiscal Quarter (pro forma prior to 2012) $0.39 $0.49 $0.58 $0.25 $0.33 $0.47 $0.53 $0.17 $0.44 $0.85 $0.74 $0.21 $0.56 $0.91 $1.05 $0.17 $0.76 $0.84 $0.87 $0.35 Q1 Q2 Q3 Q4 2008 2009 2010 2011 2012
Slide 17: Selected Balance Sheet Items (August 31, 2012)
Selected Balance Sheet Items ($ millions) August 31, 2012 August 31, 2011 Cash and cash equivalents $12.701 $10.181 Cash per share 0.786 0.537 Total current assets 14.670 13.275 Total assets 17.347 15.867 Total current liabilities 1.415 1.141 Total liabilities 2.204 1.830 Current ratio 10.4 11.6 Sha
Slide 18: Selected Balance Sheet Items (November 30, 2012)
Selected Balance Sheet Items ($ millions) November 30, 2012 August 31, 2012 Cash and cash equivalents $11.379 $12.701 Cash per share 0.695 0.787 Total current assets 13.784 14.670 Total assets 16.530 17.347 Total current liabilities 0.739 1.415 Total liabilities 1.559 2.204 Current ratio 18.6 10.4 S
Slide 19: Returning Cash to Shareholders
$1.59 $0.80 $0.80 $2.24 $1.97 $12.66 $13.24 $12.89 $12.70 $11.38 $9.33 Q4FY11 Q1FY12 Q2FY12 Q3FY12 Q4FY12 Q1FY13 $ Millions Dividend Paid Proceeds from Sale of Subsidiary Cash Returning Cash to Shareholders
Slide 20: Simulations Plus Products & Services
N H O OH O CH 3 CH 3 CH 3 Discovery Preclinical Clinical MedChem Studio ™ MedChem Designer™ GastroPlus™ DDDPlus ™ ADMET Predictor™ Simulations Plus Products & Services Consulting Services & Collaborations MembranePlus ™
Slide 21: Recent Enhancements
• Simulations Plus continues to increase its technological advantage Recent Enhancements • Version 8.0 released May 2012 • Expanded drug - drug interaction to include transporters and induction • Expanded PDPlus ™ pharmacodynamics modeling module • Expanded ocular delivery model • Expanded nasal/pul
Slide 22: Marketing and Sales Program
Marketing and Sales Program • Added Cheminformatics salesperson July 2012 to increase sales of ADMET Design Suite™ (MedChem Studio™, MedChem Designer™, and ADMET Predictor™) • Conferences/Scientific Meetings continue to be primary source of leads • During Q4 we did 14 meetings in the U.S., Europe, a
Slide 23: FDA Food Safety Research Collaboration
FDA Food Safety Research Collaboration • Completed the first year of a 5 - year renewable Research Collaboration Agreement (RCA) with Center for Food Safety and Applied Nutrition (CFSAN) to provide model - building capabilities for a large number (>70,000) of substances that can be in foods as addit
Slide 24: NCE (New Chemical Entity) Project
NCE (New Chemical Entity) Project • Using a public database courtesy of GlaxoSmithKline, and applying MedChem Studio/MedChem Designer/ADMET Predictor, we designed a number of lead candidates to inhibit the malaria parasite and qualified them for acceptable properties using only ADMET Predictor predi
Slide 25: Summary
Summary • For FY2012: - Financial performance continues our 5 - year profitable trend - Sale of Words+ has simplified and focused the business - margins increased, reporting and auditing much simpler • Continuing to Expand our Life Sciences team: - Two new Ph.D.s started in August, interviews contin
Slide 26: Q&A
Q&A simulationsplus, inc, Cf
Simulations Plus — Shareholder Meeting (February 2013) on 6ix